Pliant Therapeutics (PLRX) FY2025 10-K Risk Factors: 15 New, 9 Dropped

What the changes say

Discontinuation of the BEACON-IPF Phase 2b trial for bexotegrast drove major restructuring, cost reduction, and strategic alternatives.

What changed since the prior 10-K

New

NewRisks Related to Our Financial Position, Operations and Need for Additional Capital
Our pursuit of internal and external opportunities may not deliver the benefits we expect or enhance shareholder value
Strategic alternatives following the discontinuation of the BEACON-IPF Phase 2b trial may fail to enhance shareholder value.
NewRisks Related to Research and Development and the Biopharmaceutical Industry
Our approach to drug discovery and development of integrin-based therapeutics is unproven and may not result in a marketable product
Developing integrin-based therapeutics like PLN-101095 is unproven and may encounter unknown problems or delays.
NewRisks Related to Research and Development and the Biopharmaceutical Industry
We may be unable to obtain and maintain orphan drug designation for our product candidates and, even if we obtain such designation, we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved
We may fail to obtain or realize the benefits of orphan drug designation for our product candidates.
NewRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
The FDA or any other foreign regulatory authority may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market
Regulatory authorities may impose consent decrees, recalls, or marketing restrictions due to post-market safety issues or compliance failures.
NewRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
We are evaluating PLN-101095, and may continue to evaluate or develop current or future candidates, in combination with other therapies, which would expose us to additional risks
Evaluating PLN-101095 in combination with pembrolizumab introduces complex trial designs and attribution challenges.
NewRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
In addition, market acceptance and sales of PLN-101095 or our other product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for the product candidate and may be affected by existing and future health care reform measures
Providing benefits to healthcare professionals can violate EU anti-bribery laws and the UK Bribery Act 2010, risking fines and imprisonment.
NewRisks Related to Our Intellectual Property
application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor’s patents or patent applications
Third parties may use USPTO post-grant proceedings to invalidate our patent claims under a lower evidentiary standard.
NewRisks Related to Our Intellectual Property
product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours
The CJEU narrowed patent term extensions for second medical use, potentially reducing patent exclusivity in the EU.
NewRisks Related to Managing Our Business and Operations
As we continue to establish our business and operations at the appropriate scale, we may encounter difficulties in managing our long-term growth and any intervening changes and costs, which could adversely affect our operations
Discontinuing bexotegrast in IPF forced workforce restructuring and efforts to sublease facilities or exit the Oyster Point Lease.
NewRisks Related to Our Common Stock
Shareholder activism could cause us to incur significant expense, disrupt our business, result in a proxy contest or litigation and impact our stock price
Shareholder activism and the Rights Plan adopted on March 12, 2025, could cause significant expense, litigation, and stock volatility.
NewRisks Related to Our Common Stock
Our failure to meet Nasdaq's continued listing requirements could result in a delisting of our common stock
Failure to meet Nasdaq continued listing requirements could result in a delisting of our common stock.
NewRisks Related to Our Common Stock
We are a "smaller reporting company," and the scaled disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors
As a smaller reporting company, we rely on scaled disclosures that may make our common stock less attractive to investors.
NewRisks Related to Our Common Stock
CCPA may increase our compliance costs and potential liability, and impact our business activities depending on how it is interpreted. In the interim, implementing the evolving CPRA regulations will require additional investment in compliance programs and potential modifications to business processes
NewRisks Related to Our Common Stock
individuals’ data protection rights; and (v) an obligation to report certain personal data breaches to the competent data protection authority and affected individuals
NewRisks Related to Our Common Stock
or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of PLN-101095 or our other product candidates could be delayed

Dropped

DroppedRisks Related to Research and Development and the Biopharmaceutical Industry
Our approach to drug discovery and development in the area of fibrotic diseases, with an initial focus on tissue-specific integrin modulation and TGF-β signaling inhibition, is unproven and may not result in marketable products
DroppedRisks Related to Research and Development and the Biopharmaceutical Industry
planned trials, and may be required to further test our candidates, including additional drug-drug interaction studies, which may be expensive, time-consuming and result in delays to our programs
DroppedRisks Related to Research and Development and the Biopharmaceutical Industry
Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our future clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates
DroppedRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment
DroppedRisks Related to Our Intellectual Property
patents or other intellectual property rights or will design around the claims of patents that may issue that cover our products
DroppedRisks Related to Our Intellectual Property
information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed
Unproven approach in fibrotic diseases focusing on integrins and TGF-beta signaling.
DroppedRisks Related to Our Intellectual Property
proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party’s patent in patent opposition proceedings in the European Patent Office, or EPO, or other foreign patent office
DroppedRisks Related to Our Reliance on Third Parties
not be able to reach agreements with alternative partners or do so on terms acceptable to us. If we are unable to enter into such agreements, our research and development activities will be delayed and possibly impaired
DroppedRisks Related to Managing Our Business and Operations
We may encounter difficulties in managing our growth, which could adversely affect our operations

Reworded

90% rewrittenRisks Related to Our Reliance on Third Parties
We rely on third parties for tissue samples and other materials required for our research and development activities, and if we are unable to reach agreements with these third parties our research and development activities would be delayed
Clarified that third-party agreements are specifically for tissue samples rather than general research materials.
76% rewrittenRisks Related to Our Common Stock
Our information systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs
76% rewrittenRisks Related to Our Intellectual Property
We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful
72% rewrittenRisks Related to Our Common Stock
We may incur substantial costs in our efforts to comply with evolving global data protection laws and regulations, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations
67% rewrittenRisks Related to Our Intellectual Property
We cannot be certain that we were the first to file any patent application related to our technology, including our product candidates, and, if we were not, we may be precluded from obtaining patent protection for our technology, including our product candidates
66% rewrittenRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
Drug marketing and reimbursement regulations may materially affect our ability to market and secure reimbursement for our products
Updated to specifically name PLN-101095 alongside general product candidates regarding drug marketing and HTA regulations.
63% rewrittenRisks Related to Our Intellectual Property
Changes in patent law in the U.S. and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
56% rewrittenRisks Related to Research and Development and the Biopharmaceutical Industry
The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities
Added full agency names for HHS and CMS regarding judicial challenges following the Supreme Court APA decision.
56% rewrittenRisks Related to Our Intellectual Property
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
55% rewrittenRisks Related to Research and Development and the Biopharmaceutical Industry
Our ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in our preclinical studies and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of PLN-101095 or any of our other product candidates
Was: Our ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in our preclinical studies and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of any of our product candidates
47% rewrittenRisks Related to Our Financial Position, Operations and Need for Additional Capital
We will require substantial additional capital to fund our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations
45% rewrittenRisks Related to Research and Development and the Biopharmaceutical Industry
We may not be successful in our efforts to identify or discover additional product candidates in the future
45% rewrittenRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment. Ensuring business arrangements comply with applicable healthcare laws can be time- and resource-consuming
43% rewrittenRisks Related to Our Common Stock
We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock
42% rewrittenRisks Related to Our Intellectual Property
Patent terms may be inadequate to protect our competitive position on PLN-101095 or our other product candidates for an adequate amount of time
Was: Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
42% rewrittenRisks Related to Research and Development and the Biopharmaceutical Industry
If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
40% rewrittenRisks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance
Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations
33% rewrittenRisks Related to Research and Development and the Biopharmaceutical Industry
The design or execution of a clinical trial can determine whether its results will support marketing approval, and flaws in the design or execution of a clinical trial may not become apparent until the clinical trial is well advanced
32% rewrittenRisks Related to Research and Development and the Biopharmaceutical Industry
We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than us
28% rewrittenRisks Related to Our Financial Position, Operations and Need for Additional Capital
We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future
27% rewrittenRisks Related to Research and Development and the Biopharmaceutical Industry
Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
24% rewrittenRisks Related to Research and Development and the Biopharmaceutical Industry
A Fast Track designation by the FDA, even if granted for current or future product candidates, may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that PLN-101095 or our other product candidates will receive marketing approval
Was: A Fast Track designation by the FDA, even if granted for other current or future product candidates, may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval
23% rewrittenRisks Related to Our Common Stock
Anti-takeover provisions under our charter documents, our stockholder rights agreement, and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management
Was: Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management
21% rewrittenRisks Related to Research and Development and the Biopharmaceutical Industry
We have a limited operating history, which may make it difficult to evaluate our prospects and likelihood of success
21% rewrittenRisks Related to Managing Our Business and Operations
If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop PLN-101095 or other product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market share and could make us less competitive
Was: If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop current product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market share and could make us less competitive

All 84 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Financial Position, Operations and Need for Additional Capital

01We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future28% rewritten
02Our pursuit of internal and external opportunities may not deliver the benefits we expect or enhance shareholder valueNew
03We will require substantial additional capital to fund our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations47% rewritten
04The amount of our future losses is uncertain and our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline

Risks Related to Research and Development and the Biopharmaceutical Industry

05We have a limited operating history, which may make it difficult to evaluate our prospects and likelihood of success21% rewritten
06Our business is highly dependent on the success of the product candidates that we advance into the clinic. PLN-101095, our lead program, and our other product candidates will require significant additional development before we may be able to seek regulatory approval for and launch a product commercially
07Our approach to drug discovery and development of integrin-based therapeutics is unproven and may not result in a marketable productNew
08Clinical development involves a lengthy, complex, and expensive process, with an uncertain outcome
09We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of PLN-101095 or any other product candidates
10Our ongoing and future clinical trials may reveal significant adverse events or unexpected drug-drug interactions not seen in our preclinical studies and may result in a safety profile that could delay or prevent regulatory approval or market acceptance of PLN-101095 or any of our other product candidates55% rewritten
11If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected42% rewritten
12The design or execution of a clinical trial can determine whether its results will support marketing approval, and flaws in the design or execution of a clinical trial may not become apparent until the clinical trial is well advanced33% rewritten
13We may be unable to obtain and maintain orphan drug designation for our product candidates and, even if we obtain such designation, we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approvedNew
14A Fast Track designation by the FDA, even if granted for current or future product candidates, may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that PLN-101095 or our other product candidates will receive marketing approval24% rewritten
15Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay27% rewritten
16We may not be successful in our efforts to identify or discover additional product candidates in the future45% rewritten
17Due to our limited resources and access to capital, we must make decisions on the allocation of resources to certain programs and product candidates; these decisions may prove to be wrong and may adversely affect our business
18If product liability lawsuits are brought against us, we may incur substantial financial or other liabilities and may be required to limit commercialization of PLN-101095 or our other product candidates
19We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than us32% rewritten
20The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities56% rewritten

Risks Related to Marketing, Reimbursement, Healthcare Regulations and Ongoing Regulatory Compliance

21Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success
22Coverage and reimbursement may be limited or unavailable or pricing unfavorable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell PLN-101095 or any other product candidates profitably
23In the United States as well as foreign jurisdictions, no uniform policy of coverage and reimbursement for products exists among third-party payors
24Even if we obtain FDA approval of PLN-101095 or any of our other product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential
25The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment. Ensuring business arrangements comply with applicable healthcare laws can be time- and resource-consuming45% rewritten
26The FDA or any other foreign regulatory authority may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the marketNew
27We are evaluating PLN-101095, and may continue to evaluate or develop current or future candidates, in combination with other therapies, which would expose us to additional risksNew
28Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations40% rewritten
29Drug marketing and reimbursement regulations may materially affect our ability to market and secure reimbursement for our products66% rewritten
30In addition, market acceptance and sales of PLN-101095 or our other product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for the product candidate and may be affected by existing and future health care reform measuresNew
31Additional laws and regulations governing international operations could negatively impact or restrict our operations

Risks Related to Our Intellectual Property

32Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection
33We cannot be certain that we were the first to file any patent application related to our technology, including our product candidates, and, if we were not, we may be precluded from obtaining patent protection for our technology, including our product candidates67% rewritten
34We may enter into license or other collaboration agreements that may impose certain obligations on us. If we fail to comply with our obligations under such agreements with third parties, we could lose license rights that may be important to our future business
35If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed56% rewritten
36Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts
37Our future collaborators may assert ownership or commercial rights to inventions they develop from research we support or that we develop from our use of the tissue samples or other biological materials, which they provide to us, or otherwise arising from such collaboration
38Third parties may assert that we are employing their proprietary technology without authorization
39Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets
40Because our programs may involve product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights
41We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful76% rewritten
42Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
43Any patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO (or foreign patent offices)
44Changes in patent law in the U.S. and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products63% rewritten
45application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor’s patents or patent applicationsNew
46We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world
47Patent terms may be inadequate to protect our competitive position on PLN-101095 or our other product candidates for an adequate amount of time42% rewritten
48product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to oursNew
49If we do not obtain patent term extension, data exclusivity and orphan exclusivity for PLN-101095 or any other product candidates we may develop, our business may be materially harmed
50If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
51Intellectual property rights do not necessarily address all potential threats to our competitive advantage

Risks Related to Our Reliance on Third Parties

52If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms
53We rely on third parties for tissue samples and other materials required for our research and development activities, and if we are unable to reach agreements with these third parties our research and development activities would be delayed90% rewritten
54If we are unable to enter into new collaborations, or if these collaborations are not successful, our business could be adversely affected
55Our suppliers and any future collaborators may need assurances that our financial resources and stability on a stand-alone basis are sufficient to satisfy their requirements for doing or continuing to do business with us

Risks Related to Managing Our Business and Operations

56As we continue to establish our business and operations at the appropriate scale, we may encounter difficulties in managing our long-term growth and any intervening changes and costs, which could adversely affect our operationsNew
57If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop PLN-101095 or other product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market share and could make us less competitive21% rewritten
58Our employees, independent contractors, consultants, commercial partners, collaborators and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
59We use and generate materials that may expose us to material liability
60If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
61Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our products
62Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation

Risks Related to Our Common Stock

63The price of our stock may be volatile, and you could lose all or part of your investment
64We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock43% rewritten
65Our executive officers, directors and their affiliates and our principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
66If there are substantial sales of shares of our common stock, the price of our common stock could decline
67Anti-takeover provisions under our charter documents, our stockholder rights agreement, and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management23% rewritten
68Shareholder activism could cause us to incur significant expense, disrupt our business, result in a proxy contest or litigation and impact our stock priceNew
69Our bylaws designate certain courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to litigate disputes with us in a different judicial forum
70Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
71Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders
72If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
73Our failure to meet Nasdaq's continued listing requirements could result in a delisting of our common stockNew
74We are a "smaller reporting company," and the scaled disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investorsNew
75We incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives
76We may incur substantial costs in our efforts to comply with evolving global data protection laws and regulations, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations72% rewritten
77CCPA may increase our compliance costs and potential liability, and impact our business activities depending on how it is interpreted. In the interim, implementing the evolving CPRA regulations will require additional investment in compliance programs and potential modifications to business processesNew
78individuals’ data protection rights; and (v) an obligation to report certain personal data breaches to the competent data protection authority and affected individualsNew
79Changes in U.S. tax law could adversely affect our financial condition and results of operations
80Our information systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs76% rewritten
81or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of PLN-101095 or our other product candidates could be delayedNew
82Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations
83Use of social media platforms presents risks and challenges
84Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all

Other Pliant Therapeutics 10-Ks

FY2024 10-K risk factors
78 risks
Clinical stage biopharmaceutical company focused on discovering and developing treatments for fibrotic diseases, primarily dependent on lead candidate bexotegrast.
Filed Mar 03, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.